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ABSTRACT
PvuRts1I is a prototype for a larger family
of restriction endonucleases that cleave DNA
containing 5-hydroxymethylcytosine (5hmC) or 5-
glucosylhydroxymethylcytosine (5ghmC), but not 5-
methylcytosine (5mC) or cytosine. Here, we report
a crystal structure of the enzyme at 2.35 A˚ reso-
lution. Although the protein has been crystallized
in the absence of DNA, the structure is very infor-
mative. It shows that PvuRts1I consists of an N-
terminal, atypical PD-(D/E)XK catalytic domain and
a C-terminal SRA domain that might accommodate a
flipped 5hmC or 5ghmC base. Changes to predicted
catalytic residues of the PD-(D/E)XK domain or to the
putative pocket for a flipped base abolish catalytic
activity. Surprisingly, fluorescence changes indica-
tive of base flipping are not observed when PvuRts1I
is added to DNA substrates containing pyrrolocyto-
sine in place of 5hmC (5ghmC). Despite this caveat,
the structure suggests a model for PvuRts1I activity
and presents opportunities for protein engineering
to alter the enzyme properties for biotechnological
applications.
INTRODUCTION
The mechanistic basis of modification specific DNA bind-
ing and - in some cases - cleavage has attracted much
interest. Based on experimental structures or confident
homology models, we now have a detailed picture of
5-methylcytosine (5mC) specific binding by MBD1 (1),
MBD2 (2), MBD4 (3), MeCP2 (4), Kaiso (5) and the repli-
cation fork-associated UHRF1 (6–8). There are also struc-
tural data about 5mC specific enzymes: McrBC has been
crystallized in complex with DNA (9), and forMspJI a very
informative structure in the absence of DNA has been de-
termined (10). Based on these studies, the methyl binding
proteins/enzymes can be divided into two broad groups, de-
pending on whether they recognize the methyl group in the
context of double stranded DNA or whether they flip the
modified base to scrutinize it in a dedicated pocket. MBDs
(1–4), MeCP2 (4) and Kaiso (5) interact with the modified
base in aWatson-Crick pair. In contrast, UHRF1 andmost
likely alsoMspJI share a so-called SRA (SETandRINGas-
sociated) domain that flips and accommodates the modified
base (6–8,10). The same is true forMcrBC, even though the
flipped base binding domain is in this case not homologous
to the SRA of UHRF1 and MspJI (9).
The presence of 5-hydroxymethylcytosine (5hmC) in
phage (11) and mammalian DNA has been known for a
long time (although the initial estimates for the amount of
5hmC in mammalian DNA were too high). Much recent
research was triggered by the identification of the function
of TET (ten-eleven translocation) proteins as 5mC oxidiz-
ing enzymes (12–13), and the role of 5hmC as a demethy-
lation intermediate (14–15), epigenetic mark (16) and diag-
nostic marker in cancer (17). Recent pull-down/mass spec-
trometry studies have also shown that there is a large reper-
toire of 5hmC binding proteins in vertebrate tissues (18–
19). Some 5hmC binding proteins, such as UHRF1, bind
also 5mC, and their interaction with 5hmC can be modeled
based on the interactions with 5mC (20). Other proteins,
such as MBD3, which binds to 5hmC according to some
(21) (but not other (18)) studies, are homologous to struc-
turally characterized 5mC binding proteins and therefore
their possible interactions with 5hmC can be deduced (21).
However, for most other proteins that were identified in the
mass spectrometry experiments, it is not even clear whether
the interaction with 5hmC is direct, and provided it is, how
the 5hmC base is ‘read’. It is also still not understood how
the presence of the 5hmC base can trigger an enzymatic re-
action.
The endonuclease PvuRts1I from Proteus vulgaris
(strain) has been reported to be a dimer (22) like most
endonucleases that catalyze double strand breaks. It
cleaves DNA that contains either 5hmC or 5ghmC
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(5-glucosylhydroxymethylcytosine) bases (23), with a
preference for -5ghmC over -5ghmC (22). Cleavage is
most efficient when two 5hmC (5ghmC) bases are present
in opposite DNA strands approximately 22 bases apart
from each other (24). PvuRts1I makes a double strand
break approximately in the middle between the two sites
(the precise pattern is 5′-CN11–13↓N9–10G-3′, where the
arrow denotes the cleavage site and C the modified base)
(24). Some double strand cleavage can also be observed
when there is only a single 5hmC (5ghmC). The potential
applications of 5hmC sensitive sequencing have triggered
the search for PvuRts1I homologs that exhibit desirable
properties for biotechnological use. This search has led to
the identification of a whole family of enzymes, which differ
slightly in the distance requirement for the modified bases
(25). In contrast to PvuRts1I, some of them such as AbaSI
show a preference for 5ghmC over 5hmC (25), which can
be exploited in sequencing by postglucosylation of 5hmC
with phage T4 glucosyltransferase. All tested members of
the PvuRts1I family discriminate between 5hmC and 5mC,
but to varying degrees. As 5hmC is much rarer than 5mC in
animal genomes (26), very high discrimination stringency
is required for biotechnological use. Hence, there are at
least two engineering goals to improve PvuRts1I and/or
the other family members. First, it would be desirable to
design an enzyme fully dependent on a single modified
site only, which should make a double strand break on
one or both sides of the modified base. Second, it would
be useful to improve the stringency of 5hmC versus 5mC
discrimination.
Here, we report the crystal structure of PvuRts1I at
2.35 A˚ resolution. The structure reveals an N-terminal PD-
(D/E)XK domain in agreement with an earlier prediction
(27) and a previously unrecognized C-terminal SRA do-
main. Site-directed mutagenesis experiments confirm the
importance of predicted key residues in the structure. Based
on the combined crystallographic and biochemical data, we
suggest a structural explanation for why PvuRts1I requires
5hmC or 5ghmC bases in opposite strands at a distance
of just over 20 base pairs for the introduction of a double
strand break approximately halfway between the modified
bases.
MATERIALS AND METHODS
Cloning
A codon optimized PvuRts1I REase (pvuRts1I) synthetic
gene in pTriEx (Apr) vector was purchased from Mr. Gene
(Germany). The gene was introduced into pET15bmod
(Apr), a derivative of pET15b (+) (Apr) via EcoRI andXhoI
restriction sites, resulting in a construct coding for the pro-
teinwithN-terminalMGHHHHHHEF tag. The same gene
was also cloned into pET28a (+) (Knr) via NcoI and XhoI,
leading to a construct for a proteinwith slightlymodifiedN-
terminus (MGSK. . . ) and C-terminal tag (LEHHHHHH).
Mutants of pvuRts1Iwere generated in the construct for the
N-terminally tagged protein variant using the QuikChange
protocol (28).
Protein expression
Expression experiments were done in Escherichia coli
strain ER2566 (F- - fhuA2 [lon] ompT lacZ::T7 gene
1 gal sulA11 (mcrC-mrr)114::IS10 R(mcr-73::miniTn10-
TetS)2 R(zgb-210::Tn10)(TetS) endA1 [dcm]) (from New
England Biolabs). The strain was transformed with plas-
mids coding for the N- or C-terminally tagged versions of
the PvuRts1I protein. Cells were grown in LBmedium with
50 g/ml ampicillin at 37◦C to OD600 of 0.6 and induced
with between 0.1 and 1mMIPTG. The expressionwas high-
est when cells were grown for 4 h at 22◦C. Cells were har-
vested by centrifugation and the pellet was stored at -20◦C.
Expression of the selenomethionine version of PvuRts1I
(with N-terminal tag) was done in methionine auxotrophic
BL834(DE3) cells in defined media lacking methionine and
supplemented with selenomethionine (29).
Protein purification
Frozen cells expressing PvuRts1I were thawed and resus-
pended in buffer A (20 mM Tris/HCl pH 7.6, 400 mM
NaCl and 1 mM PMSF). Cells in suspension were opened
by sonication and the cell debris was removed by centrifu-
gation at 145000×g for 30 min. PvuRts1I was purified by
affinity chromatography on nickel nitrilotriacetic acid (Ni-
NTA) agarose resin (Qiagen). The protein was eluted in
a gradient of imidazole (30 mM to 300 mM) in buffer
B (20 mM Tris/HCl pH 7.6, 200 mM NaCl and 7 mM
2-mercaptoethanol). Fractions containing PvuRts1I were
combined and concentrated using Vivaspin concentrators
(10 kDa MWCO). The protein was purified further by size
exclusion chromatography on HiLoad 16/60 Superdex 75
column (GE Healthcare), equilibrated with buffer C (20
mM Tris/HCl pH 7.6, 200 mM NaCl, 1 mM EDTA and
1 mM DTT). Fractions containing PvuRts1I were pooled
and concentrated to 20–24 mg/ml. From 1 liter of culture,
∼7 mg of protein was obtained that appeared pure on a
Coomassie-stained SDS-PAGE gel. The variant proteins
were obtained according to the protocol for the wild-type.
Crystallization
PvuRts1I was concentrated to 23mg/ml and then the buffer
was supplemented with 0.2 M glucose. Crystals were grown
at 18◦C by the hanging drop method. A mix of 2 l of pro-
tein solution and 2 l of reservoir buffer was equilibrated
against reservoir buffer containing 10% w/v PEG 4000,
20% v/v glycerol, 20 mM D-glucose, 20 mM D-mannose,
20 mMD-galactose, 20 mM L-fucose, 20 mMD-xylose, 20
mM N-acetyl-D-glucosamine and 0.1 M MOPS/HEPES-
Na pH 7.5. For cryo-protection, crystals were transferred to
modified reservoir buffer supplemented with 28% instead of
20% v/v glycerol.
Structure determination
Crystals belonged to space group P4(1)2(1)2 with cell di-
mensions a = b ≈ 62 A˚, c = 211 A˚ and contained
one molecule of PvuRts1I in the asymmetric unit. They
diffracted to approximately 3 A˚ resolution. In the absence
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of suitable models for molecular replacement, experimental
phasing was required. Therefore, we grew crystals of the se-
lenomethionine variant of the protein (containing four sele-
nium atoms not counting the initiator methionine upstream
of the histidine tag), which turned out to be better than
the wild-type protein crystals and diffracted to 2.35 A˚ res-
olution. Diffraction data were collected at a wavelength of
0.97625 A˚, which is just above the selenium edge in energy.
The structure was solved by the single anomalous diffrac-
tion (SAD) method. Selenium sites were localized using the
SHELXD program (30). The SHELXE program (31) was
then used to generate an experimental electron density map
by a combination of phasing and densitymodification steps.
The density was interpreted automatically using PHENIX
(32), leading to a nearly complete model of PvuRts1I lack-
ing only a few loops. The model was completed and im-
provedmanually and refinedwith the COOT (33) andREF-
MAC (34) programs (Supplementary Table S1). The final
model coordinates and the corresponding structure factors
were deposited at Protein Data Bank (PDB) with the 4OQ2
accession code.
Assay of the PvuRts1I mutants against T4 phage genome
T4 phage DNA was purified according to a published pro-
tocol (35). All the mutants and the wild-type protein were
loaded on the SDS gel to show the equal concentration of
the proteins. Approximately 0.1 g (low) and 1 g (high)
amounts of protein were mixed with 240 ng of T4 phage
genome in the buffer containing 50 mM potassium acetate,
20 mM Tris-acetate, 10 mM magnesium acetate and 1 mM
DTT, pH 7.9. The reactions were incubated at 23◦C for 20
min. The reaction mixtures were loaded to 1% agarose gel
and visualized by Gel Red (Biotium Inc.) staining.
RESULTS
PvuRts1I expression and biochemical characterization
A synthetic gene was used to overexpress versions of
PvuRts1I with N-terminal or C-terminal hexahistidine tags
inE. coli strain ER2566. The proteins were purified by affin-
ity and size exclusion chromatographies. The purified re-
combinant wild-type proteins with tags on either end, but
not controls with changes to important residues, were active
against T4 phage DNA, which is known to contain a large
number of 5ghmC bases at various distances to each other.
Although protein activities were at least qualitatively in
agreement with the literature data, the variant of PvuRts1I
with N-terminal hexahistidine tag had some other unex-
pected properties, at least in our hands. While PvuRts1I
should be a dimer also in the absence of DNA (22), size
exclusion chromatography with the N-terminally tagged,
but not the C-terminally tagged, variant of the enzyme
suggested a slightly lower than expected molecular mass.
We also observed a high and unspecific affinity for DNA
(hydroxymethylated, methylated and non-methylated DNA
are all bound) (Supplementary Figures S1 and S2). De-
spite these undesirable features of the N-terminally tagged
PvuRts1I, we continued work with this variant of the pro-
tein, because it yielded well-diffracting crystals, at least in
the absence of DNA.
Crystallization and structure determination
Crystallization of PvuRts1I was attempted either in the
absence of DNA or with oligonucleotides containing two
5hmC bases at the appropriate distance. We either avoided
divalent metal cations or used Ca2+ ions, which support
DNA binding, but not cleavage. Finally, we also set up crys-
tallization trials with oligoduplexes that represent PvuRts1I
cleavage products (except for the 5′-phosphates), in the pres-
ence of either Mg2+ or Ca2+ ions. All these experiments
did not yield any diffracting crystals. We concluded that
PvuRts1I might have a flexible substrate binding site, and
because we knew that the enzyme accepted 5ghmC contain-
ing DNA, we tried crystallization in the presence of large
amounts of glucose. This proved crucial for crystallization
success. Crystals belonged to space group P4(1)2(1)2, con-
tained onemolecule of PvuRts1I in the asymmetric unit and
diffracted up to 2.35 A˚ resolution. The structure was solved
by the SADmethod using a crystal of the selenomethionine
version of the protein.
Gross structure of PvuRts1I
The crystal structure reveals that PvuRts1I is a two-domain
protein (Figure 1). We carried out DALI searches with the
two domains against the PDB database of protein struc-
tures (36). The results indicate significant structural simi-
larity between the N-terminal domain of PvuRts1I and sev-
eral PD-(D/E)XK endonucleases (DALI Z-scores of 6.9 for
Ngo0050 from Neisseria gonorrhoeae, 4.9 for V.EcoKDcm,
4.2 for Hjc, 2.7 for PspGI and 2.5 for NgoMIV), in agree-
ment with the inclusion of PvuRts1I in a bioinformatic sur-
vey of highly diverged PD-(D/E)XK restriction endonucle-
ases (27). We therefore conclude that the N-terminal part
of the enzyme (residues 1–140) harbors the nuclease ac-
tivity and henceforth refer to it as the catalytic domain.
The DALI search also revealed a previously unrecognized
clear structural similarity between the C-terminal part of
PvuRts1I and various SRA domain proteins (DALI Z-
scores for the corresponding domains: 7.0 for SUVH5, 6.5
for UHRF1, 6.1 for MspJI and 6.0 for UHRF2). There-
fore, the C-terminal domain of PvuRts1I (residues 141–293)
will be referred to as its SRA domain in the following. As
SRA domains recognize modified bases by flipping them
out of the DNA stack into a pocket of the domain (6–8),
the PvuRts1I could also be a nucleotide flipping enzyme.
Structure of the nuclease domain and active site prediction
PD-(D/E)XK restriction endonucleases are named for the
(typically) conserved residues in the active site, which are
found in canonical secondary structure contexts. The core
folding motif of PD-(D/E)XK restriction endonucleases
consists of an -helix that is followed by three consecutive
-strands, which together form an antiparallel -sheet (of-
ten with additional strands outside the core motif) (Fig-
ure 1). The PvuRts1I catalytic domain contains the PD-
(D/E)XK motif and, as predicted by the bioinformatic
analysis (27), has candidate active site residues in the ex-
pected places (with the exception of the lysine) (Figure 2).
The first catalytic residue, a glutamate in -helical context
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Figure 1. PvuRts1I domains and homologs. (A) PvuRts1I catalytic (residues 1–140) and SRA (residues 141–293) domains are in yellow and green,
respectively. Core elements of the fold are in bright and additional elements in faint color. (B) PspGI restriction endonuclease, a homolog of PvuRts1I
catalytic domain. (C) SRA domain of UHRF1, a homolog of PvuRts1I SRA domain (6–8). (D) Alignment of the amino acid sequences of PvuRts1I
catalytic core and homologs. (E) Alignment of the SRA domain sequences in the pocket region. The PvuRts1I-AbaSI alignment is sequence based, all
other alignments are structure based.
Figure 2. Active site. PvuRts1I (A, yellow) and BcnI as bona fide PD-
(D/E)XK endonuclease with DNA (B, gray) in all-atom representation.
The thin lines in the PvuRts1I panel indicate the positions of the corre-
sponding residues and substrate DNA in the BcnI structure.
that is not cited in the PD-(D/E)XK consensus, is Glu20.
The ‘PD’ aspartate, which coordinates one or both metal
ions in the PD-(D/E)XK family, is Asp57 (sequence con-
text ADLL) at theN-terminal end of the second -strand of
the coremotif. The canonical ‘(D/E)XK’motif in PvuRts1I
is changed to ‘EID’, with Glu68 in the role of the acidic
residue of the motif and an aspartate in the place of the ex-
pected lysine residue. There is a lysine residue (Lys17) else-
where in the sequence that is spatially in the proximity of the
active site, but the -amino group is not in the expected lo-
cation. Metal ions are not present in the active site because
crystals were grown in the absence of divalent metal ions.
Identification of active site residues by site-directed mutage-
nesis
Candidate catalytic residues and Glu71, an acidic residue
without clear function in the PD-(D/E)XK motif, were in-
Figure 3. Effect of mutations on PvuRts1I activity. PvuRts1I and its vari-
ants were either analyzed for protein purity by SDS-PAGE and Coomassie
staining (top, 3 g per lane) or used to digest 240 ng of phage T4 DNA,
which was then analyzed by gel electrophoresis in a 1% agarose gel and
stained with Gel Red. For each variant, two protein amounts (0.1 g, left;
1 g, right) were tested.
dividually replaced by alanines. The activity of the resulting
variants was tested with T4 phage DNA as a substrate in
conditions that lead to complete DNA cleavage by the wild-
type enzyme (Figure 3). As expected, replacement of Glu20
or Asp57 with alanine strongly reduced or abolished activ-
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Figure 4. SRAdomain pocket. PvuRts1I (A, green) andUHRF1 (B, gray)
in all-atom representation. The flipped 5mC base in the UHRF1 pocket
is observed in the crystal structure. In contrast, the 5hmC base in the
PvuRts1I pocket has been modeled based on the superposition of the two
structures (A, thin lines).
ity. The role of the Glu68 in catalysis could not be directly
tested because the Glu68Ala variant of PvuRts1I could not
be made in soluble form in E. coli. Mutation of Glu71
also abolished activity, and at most residual activity was
seen when Lys17 was mutated to alanine. We conclude that
the mutagenesis experiments support the bioinformatic-
(27) and crystallography-based identification of active site
residues. These residues were also noted, but not singled
out, in an earlier study of amino acid conservation in the
PvuRts1I family (25).
Structure of the SRA domain and model for the DNA recog-
nition
The C-terminal domain of PvuRts1I has the typical SRA
domain fold. It is organized around a central, mixed-sheet
with additional smaller -sheets and some helices wrapped
around it. Among the SRAdomains, the binding toDNA is
experimentally best characterized forUHRF1 (6–8).Hence,
we superimposed the SRA domain of PvuRts1I onto the
UHRF1-DNA co-crystal structure and checked the loca-
tion of the flipped base (Figure 4). This analysis reveals
that PvuRts1I has indeed a pocket in the expected loca-
tion, with sufficient space for 5hmC (Figure 4 and Sup-
plementary Figure S3). The pocket is formed mainly by
Pro207, Trp205, Trp215, Asn217 and Glu228. A poten-
tially flipped base could make hydrophobic contacts with
Trp215 from one side and Pro207 and Trp205 on the other.
The 5hmC Watson–Crick edge might be recognized by
Asn217, Glu228 and Arg208. The modeling also shows that
there is extra space in the PvuRts1I pocket, so that even
5ghmC might fit in. Given the uncertainties of the mod-
eling (only 13% sequence identity between the SRA do-
mains of PvuRts1I and UHRF1), we cannot pinpoint the
precise location of the hydroxyl or glycosylhydroxyl group,
but Trp205, Arg244, Tyr237 and Glu228 are candidate in-
teraction partners for hydrogen bonding. Interestingly, we
see an isolated large peak of electron density close to the ex-
pected location of the glucosylhydroxymethyl group in the
pocket for the flipped base. Unfortunately, the resolution of
the structure is not sufficient to decide whether this peak is
due to a partially disordered glucosemolecule (whichwould
explain why it was essential for crystallization).
Tests of nucleotide flipping and the SRA pocket function
The detection of an SRA domain in PvuRts1I strongly sug-
gests that the protein flips the 5hmC or 5ghmC bases in
its target sequence for detailed scrutiny, as suggested for
UHRF1 (6–8) and SUVH5 (38) (based on crystallographic
evidence) and for MspJI (10) (based on modeling). We first
attempted to directly demonstrate nucleotide flipping using
DNA with the environment sensitive fluorophore pyrrolo-
cytosine (pyC) instead of the 5hmC in either one or both
DNA strands. Preliminary experiments showed that pyC
and 5hmC could both direct the cleavage of DNA oligodu-
plexes. With the 5hmC substrate (and a mixed 5hmC/pyC
substrate) we observed two cleavage sites, one in the ex-
pected position and another one closer to the 5hmC base.
With the pyC/pyC substrate, only the non-canonical cleav-
age closer to the base was observed (Supplementary Figure
S4A). The pattern was not affected by the location of the
histidine tag at either N- or C-terminus of PvuRts1I. Un-
fortunately, there was no significant increase of pyC fluo-
rescence when PvuRts1I was added in the absence of diva-
lent metal cations (Supplementary Figure S4B). This result
is consistent with pyC (and by implication 5hmCor 5ghmC)
not being flipped. However, it could also be due to the non-
canonical cleavage for pyC substrates, to efficient quenching
of the fluorescence by the SRA domain or to unintended
tertiary structure of the oligoduplex (which eluted from a
gel filtration column in several peaks).
As the pyC fluorescence experiments were inconclusive,
we carried out mutagenesis experiments. According to the
crystal structure Trp205, Trp215 and Glu228 might con-
tribute to shaping the walls of the PvuRts1I pocket. In
contrast, Arg208 contributes to the pocket primarily by its
main chain, but not by the side chain, which points away
from it. We separately changed all four residues to alanines.
The Trp205Ala substitution made PvuRts1I insoluble, but
the other variants could be assayed. The Arg208Ala muta-
tion was only mildly compromised in its activity, but both
the Trp215Ala and Glu228Ala mutations lost activity com-
pletely (Figure 3), as one would predict if the pocket of
the SRA domain was required to accommodate the mod-
ified cytosine base. We conclude that the mutagenesis ex-
periments support the hypothesis that the SRA domain of
PvuRts1I flips the 5hmC or 5ghmC bases in a substrate.
DISCUSSION
A variant PD-(D/E)XK domain in PvuRts1I
The classification of PvuRts1I as a PD-(D/E)XK endonu-
clease is consistent with an earlier prediction (27) and sup-
ported by biochemical findings and the structural data. As
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Figure 5. Models for the PvuRts1I dimer bound to targetDNA. (A) BentDNAand PvuRts1I with linker conformation observed in the crystal. (B) Straight
DNA and PvuRts1I with adjusted interdomain linker. Nuclease domains (with modeled metal ions) were placed on the DNA based on the superposition
with the NgoMIV-DNA complex (37). The binding mode of the DNA to the SRA domain is modeled after the UHRF1-DNA complex.
noticed earlier and confirmed in this work, PvuRts1I is ac-
tive in the presence ofMg2+, but not Ca2+ ions (Supplemen-
tary Figure S5). This is typical for PD-(D/E)XK restric-
tion endonucleases, but would not be expected for HNH
(also called -Me), GIY-YIG or phospholipase like nu-
cleases. The assignment is further supported by the pres-
ence of the core  folding motif in the catalytic domain
of PvuRts1I and by the presence of candidate active site
residues (with the exception of the lysine) in their expected
locations.
Modification specific SRA domain, unspecific nuclease do-
main
PvuRts1I cleaves DNA approximately 11–13 nucleotides
from 5hmC or 5ghmC bases. Taking the typical distance be-
tween adjacent base pairs as 3.4 A˚ (as in ideal B-DNA) and
assuming straight DNA, the cleavage site is expected to be
30–45 A˚ away from the modified base. This distance is com-
parable to or larger than the largest linear dimension of the
PD-(D/E)XK domain and therefore makes it unlikely that
the nuclease domain is directly involved in sensing theDNA
modifications. This suggests that the 5hmC or 5ghmC bases
are ‘read’ by the SRA domain, in agreement with earlier
findings for homologous domains of UHRF1 and MspJI,
which are specific for modified DNA bases. Unfortunately,
the isolated domains of PvuRts1I could only be expressed
in insoluble form, and thus this model of PvuRts1I activity
could not be directly tested biochemically.
A model for PvuRts1I catalytic domain–DNA complex
Based on prior co-crystal structures of PD-(D/E)XK do-
main restriction endonucleases with substrate DNA, such
as the NgoMIV-DNA co-crystal structure (37), it is possi-
ble to place the PvuRts1I nuclease domain on the DNA in
a ‘productive’ orientation (Figure 5). In fact, such modeling
results in protein–DNA clashes only in the region of a sin-
gle helix of the enzyme, which could move to the DNAma-
jor groove upon complex formation. The predicted DNA
binding mode is also consistent with calculations of the sur-
face properties of the protein, once the metal cations that
are expected in the active site of a PD-(D/E)XK endonu-
clease (but were absent from the crystallization buffer) are
included in the calculation (Supplementary Figure S6). As
the stagger between the two single strand cuts is known (2-
nt 3′-overhangs in the product) (25), the modeling also de-
fines the relative orientation of the PD-(D/E)XK domains
with respect to each other. In support of the model, result-
ing clashes between the nuclease domains appear resolvable
by local rearrangements (Figure 5).
In agreement with the biochemical data for the PvuRts1I
variant used in this work, we do not find the predicted
dimer in the crystal. There is a crystallographic neighbor
of the single molecule in the asymmetric unit in roughly
the expected position, but its orientation is completely un-
like what one would expect for a productive dimer. More-
over, the PISA server (39), which analyzes protein–protein
contacts in a crystal, scores none of the interfaces in the
PvuRts1I crystal as biologically relevant and classifies the
protein as a monomer. The protein used in this work differs
only by theN-terminal histidine tag from protein character-
ized previously (produced with an intein tag cleaved off dur-
ing purification) (22). A comparison of the gel filtration pat-
terns of N- and C-terminally tagged PvuRts1I suggests that
the N-terminal tag slightly destabilizes the dimer. Thus, it
appears that the tag, despite not being located in the dimer-
ization interface, together with crystallization forces could
be responsible for the unusual monomeric state of the pro-
tein in the crystal.
A model for the full-length PvuRts1I dimer with bound DNA
Based on the co-crystal structure of the UHRF1 SRA do-
main with DNA (6–8), we can also model DNA bound to
this domain of PvuRts1I. The next step then is to connect
the DNA duplexes bound to the SRA and PD-(D/E)XK
domains of the enzyme. Reassuringly, the biochemically
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predicted number of base pairs is very suitable to bridge
the distance between the cleavage sites and the positions
of the modified bases on the two DNA strands, provided
that the DNA is sufficiently bent between the two regions
(Figure 5A). Alternatively, a plausible model can also be
built if PvuRts1I interdomain linkers are taken to be flexible
and the domain orientations are adjusted so that the pro-
tein binds straight B-DNA (Figure 5B). We also note that
the predicted DNA binding sites of both domains are qual-
itatively supported by calculations of the PvuRts1I electro-
static surface, which has clear patches of positive charge in
these regions (Supplementary Figure S6). We presume that
these parts of the protein are involved in interactions with
the negatively charged phosphodiester backbone of DNA
and account for the observed high unspecific DNA affinity.
The modeling data appear compatible with a
FokI/TALEN-like (40) model for PvuRts1I activity
(apart from the order of domains, catalytic domain is
N-terminal in PvuRts1I and C-terminal in TALENs).
According to this view, the SRA domains of the PvuRts1I
dimer act as the modification specific counterparts of the
sequence specific TAL domains, and the nuclease domains
play the role of the FokI domains of the TALEN pair. The
higher activity of PvuRts1I against substrates with two
rather than one modified base could be an avidity effect,
or might be attributed to an activating ‘kissing interaction’
between the nuclease domains (41).
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